Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults.
As usual NHS Choices’ Behind the Headlines offers due perspective, without over-dampening readers’ enthusiasm.
Promising Alzheimer’s drug ‘clears early hurdle’. London: NHS Choices; Behind the Headlines, November 3rd 2016.
This relates to:
Kennedy, ME. Stamford, AW. [and] Chen, X. [et al] (2016). The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Science Translational Medicine. November 2nd 2016. [Epub ahead of print].
Possibly of interest:
Yan, R. (2016). Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs. Translational Neurodegeneration. July 2016. 14(5): 13.
Trials Halted in 2018
Hopes dashed: further development of the drug has since stopped.
“An external Data Monitoring Committee (eDMC) had recommended halting the trial after an interim safety analysis found the likelihood of benefits didn’t outweigh the risks”.
Terry, M. (2018). Phase III APECS study investigating verubecestat for Alzheimer’s Disease fails to meet primary endpoint. [Online, USA]: Biospace Inc., February 19th 2018.